loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Perflutren

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Perflutren

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Lantheus Announces the Approval of DEFINITY by China’s NMPA
    Lantheus Announces the Approval of DEFINITY by China’s NMPA

    28 Nov 2022

    // PRESS RELEASE

    https://lantheusholdings.gcs-web.com/news-releases/news-release-details/lantheus-announces-approval-definityr-perflutren-lipid

    PRESS RELEASE
    28 Nov 2022
    Share Share
    FDA Approves GE Healthcare for Contraindications in PI for Optison
    FDA Approves GE Healthcare for Contraindications in PI for Optison

    05 Oct 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20211005005646/en

    BUSINESSWIRE
    05 Oct 2021
    Share Share
    Health Canada Issues Class II Drug Recall of Alburex-25 Solution
    Health Canada Issues Class II Drug Recall of Alburex-25 Solution

    11 Feb 2019

    // HEALTH CANADA

    https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2019/69014r-eng.php

    HEALTH CANADA
    11 Feb 2019
    Share Share